TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients wit...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancers (Basel)
Κύριοι συγγραφείς: Del Bianco, Paola, Stagni, Camilla, Giunco, Silvia, Fabozzi, Alessio, Elefanti, Lisa, Pellegrini, Stefania, Vecchiato, Antonella, Pigozzo, Jacopo, Zamuner, Carolina, De Rossi, Anita, De Nicolo, Arcangela, Menin, Chiara
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: MDPI 2020
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226422/
https://ncbi.nlm.nih.gov/pubmed/32290374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040946
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια